Please select the option that best describes you:

For which non-BRCA pathogenic germline variants, if any, might you consider recommending chemoprevention with SERM/AI?  

In a scenario where patient's other clinical/familial risk does not sufficiently qualify them?

See JCO OGR 8/2021 by @Mark E. Robson discussing management of non-BRCA PVs, and companion study (Kraft et al, 8/2021) evaluating the role of further characterization of polygenic risk score.



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
When counseling a BRCA1 and BRCA2 patient who is n...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Southwest Medcl Consult SC
Specific details provided by Dr. @Katherine D. Cre...
Sign in or Register to read more